What is kymriah's duration in patient's system?

Short answer: there isn’t a fixed “duration” like with a typical pill. Kymriah is a CAR-T cell therapy made from the patient’s own T cells, which are infused back into the body and can persist for varying lengths of time—from weeks to years in different people.

Key points:
- After infusion, CAR-T cells usually expand over the first 1–2 weeks and may peak around 1–3 weeks.
- They can persist long-term; many patients have detectable CAR-T cells for months and some for years.
- Persistence often correlates with durable responses and with B-cell aplasia (absence of B cells) as long as CAR-T cells remain.
- If CAR-T cells wane, B-cell recovery may occur, and there is a potential risk of relapse in some cases.
- Monitoring typically includes blood tests to detect CAR-T cells (by flow cytometry or PCR), as well as antibody (immunoglobulin) levels and clinical assessments for side effects like CRS or neurotoxicity.
- Long-term follow-up is recommended for safety and to track durability of response; exact follow-up durations can be specified by the treating center and regulatory guidelines.

If you’re asking about a specific patient or need numbers from the label or studies, I can pull those details or help interpret them.